Oropharyngeal and esophageal mucositis: an infrequent ablative after-treatment complication with ¹³¹I

Ablation treatment with radioiodine (TARY) consists of oral administration of sodium iodide (¹³¹INa) in order to selectively irradiate the remaining thyroid tissue in patients with differentiated thyroid carcinoma (DTC) after surgical thyroidectomy or tumor recurrence. We present a case of a 61-year-old woman who underwent treatment for papillary carcinoma of the thyroid, follicular variant, using total thyroidectomy and lymphadenectomy, who was referred for an ablative dose of ¹³¹INa after the administration of recombinant TSH. Six days after the administration of ¹³¹INa, the patient began with a picture of difficulty in swallowing, oropharyngeal and esophageal pain, accompanied by erythema and ulcerative lesions at those levels, composing a pattern suggestive of type I hypersensitivity